Page 2,674«..1020..2,6732,6742,6752,676..2,6802,690..»

Everyone At Risk From Mad Cow Disease

Posted: August 12, 2012 at 3:51 pm

By John von Radowitz, Science Correspondent, PA News

No one is immune to the human form of mad cow disease, variant CJD, new research suggests today.

Some people whose genetic make-up normally acts as a barrier against infection may ultimately develop a different and so-far unrecognised type of disease, it is claimed.

Scientists have shown that individuals with a pair of genes known as MM about a third of the population acquire vCJD relatively easily.

No one with a different paring, VV, has been known to suffer the disease.

Then in August it emerged that a patient from a mixed MV genetic group had been infected with vCJD from contaminated blood, without showing any symptoms. Just over half the population has the MV pairing.

The news sparked fears of a mad cow disease timebomb in the population, with thousands of people unwittingly carrying the brain disease on a long incubation fuse. Read more…

Source:
http://feeds.feedburner.com/integratedmedicine

Posted in Integrative Medicine | Comments Off on Everyone At Risk From Mad Cow Disease

Is the cell therapy sector outperforming the major indices?

Posted: August 12, 2012 at 3:51 pm


So here's what I did today.  I built a portfolio of public companies focused exclusively or predominately in the cell therapy space.  I excluded any companies that are in the sector but their products/services constitute less than a significant majority of their revenue and/or expenses.  The portfolio sits at 29 companies.  Here's the list:


Here's how the portfolio performs against the Dow Jones, Standard and Poor's, and NASDAQ indices so far this year.


When looking at the period 1 January 2012 to 10 August 2012, the cell therapy portfolio is up 42%, Dow Jones up 8%, Standard and Poor's up 12% and NASDAQ up 16%.

In the context of how much we hear about how harsh this sector is or has been on investors, I found today's analysis interesting and, honestly, pleasantly surprising.

This snapshot is useful but has its limitations. I'm relying on Google Finance for accuracy of the information provided.  Do your own due diligence. Invest accordingly.  I hope this helps.

--Lee

This snapshot has been brought to you by Cell Therapy Group: all cell therapy, all the time! 🙂

Source:
http://feeds.feedburner.com/CellTherapyBlog

Posted in Regenerative Medicine | Comments Off on Is the cell therapy sector outperforming the major indices?

Researcher Alert: Opportunity for Fresh Appeal in $243 Million Disease Team Round

Posted: August 12, 2012 at 3:51 pm


A tiny opening exists for scientists
who failed to win approval last month of their bids for $20 million
research awards from the California stem cell agency.

On July 26, the agency's governing
board okayed $151 million for eight scientists during a day filled
with emotional testimony from patients, as well as appeals by
researchers seeking reconsideration of rejection by grant reviewers
at the California Institute for Regenerative Medicine. The board also
asked reviewers to take a fresh look at five applications in its signature disease team round.
However, the board failed to act on
eight applications, meaning that they are still pending. Normally the
board will approve -- as a group -- one set of applications. Then, at
the same meeting, it will vote to reject another set of applications.
On July 26, however, the hard-pressed directors late in the
afternoon lost the supermajority quorum (65 percent) required to do
business and adjourned without acting on all the applications.
This situation rarely occurs on award
rounds. In our recollection, it has happened only once before
although there may have been other occasions.
That leaves an opening for more
researchers to ask the board to act favorably at its Sept. 5-6 meeting in San Francisco on applications rejected by reviewers. Money
is available. The July 26 round was budgeted for $243 million.
At the meeting last month, discussion
by directors provided several clues to appropriate avenues for
reconsideration. They were interested in appeals, formally called
extraordinary petitions, that brought genuinely new information to
the table. Serious errors in the reviews – something more than
differences of opinion – were of interest. Wide variance in the
spread of scientific scores on specific applications, including the
preliminary scores, also triggered directors' interest.
Researchers considering appeals would
be well-advised to listen to the audiocast of the meeting to hear the
discussion of appeals. The transcript of the meeting also should be
posted soon on the CIRM website, probably this week. The transcript
can be found via this page when it is posted. The audiocast
instructions can be found on the July 26 meeting agenda.
(The best available information on the
CIRM web site shows a Sept. 5-6 governing board meeting. However,
that schedule also shows other two day meetings earlier this year,
which actually have turned out to be only one day.)

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Researcher Alert: Opportunity for Fresh Appeal in $243 Million Disease Team Round

Stem cells may help prevent post-injury arthritis

Posted: August 12, 2012 at 3:15 am

Researchers may have found a promising stem cell therapy for preventing osteoarthritis after a joint injury.

Injuring a joint greatly raises the odds of getting a form of osteoarthritis called post-traumatic arthritis, or PTA. There are no therapies yet that modify or slow the progression of arthritis after injury.

Researchers at Duke University Health System have found a very promising therapeutic approach to PTA using a type of stem cell, called mesenchymal stem cells (MSCs), in mice with fractures that typically would lead to them developing arthritis.

Their findings could lead to a therapy that would be used after joint injury and before signs of significant osteoarthritis.

The scientists thought the stem cells would work to prevent PTA by altering the balance of inflammation and regeneration in knee joints, because these stem cells have beneficial properties in other regions of the body.

"The stem cells were able to prevent post-traumatic arthritis," said Farshid Guilak, Ph.D., director of orthopaedic research at Duke and senior author of the study.

The researchers also thought that a type of mice bred for their super-healing properties would probably fare better than typical mice, but they were wrong.

"We decided to investigate two therapies for the study, said lead author Brian Diekman, Ph.D., a postdoctoral researcher in the Guilak lab.

"We thought that stem cells from so-called superhealer mice would be superior at providing protection, and instead, we found that they were no better than stem cells from typical mice. We thought that maybe it would take stem cells from superhealers to gain an effect as strong as preventing arthritis after a fracture, but we were surprised and excited to learn that regular stem cells work just as well," he said.

Certain people appear to fall into the superhealer category, too. They bounce back quickly and heal well naturally after a fracture, while other people eventually form cases of arthritis at the fractured joint, said Guilak, who is a professor of orthopaedic surgery and biomedical engineering.

The rest is here:
Stem cells may help prevent post-injury arthritis

Posted in Stem Cell Therapy | Comments Off on Stem cells may help prevent post-injury arthritis

A Growth-Free Quarter — and That's OK

Posted: August 11, 2012 at 10:10 am

While $34.7 million is a touch more than $34.5 million, that's not exactly huge quarter-over-quarter growth from Seattle Genetics' (Nasdaq: SGEN) Adcetris.

Still, investors seem to be shaking off the lackluster growth, and for good reason: Sales of Adcetris -- a drug for treating relapsed Hodgkin lymphoma and anaplastic large-cell lymphoma -- are a very small part of the long-term success of Seattle Genetics.

The light growth seems to be the result of declining business at academic centers, where sales dropped off as patients stopped treatment because they finished their therapy cycles or had a strong enough response to undergo a stem-cell transplant.

The number of community doctors using the drug increased in the second quarter, which is good news for the sales trajectory, as most of the lymphoma patients for whom Adcetris is appropriate are seen in the community setting.

Don't expect much growth in the second half, though; management is guiding for sales of $140 million to $150 million in 2012 -- either flat or a 17% increase from the first half of the year to the second half.

Seattle Genetics lost $12.3 million on a GAAP basis in the quarter but didn't actually burn any cash. In fact, the cash, cash equivalents, and investments increased by $21.5 million during the quarter. I don't know how long investors can expect that to continue, as the biotech is still using product manufactured prior to approval.

Of course, aside from Adcetris, Seattle Genetics can bring in cash by licensing out its antibody-drug conjugate technology, which has attracted some big names, including Roche, GlaxoSmithKline (NYSE: GSK) , Pfizer (NYSE: PFE) , and Abbott Labs (NYSE: ABT) .

Internally, Seattle Genetics' future depends on expanding the use of Adcetris into frontline setting for the two lymphomas it's currently approved to treat, as well as other types of cancer. The potential there towers over the $150 million Seattle Genetics will bring in this year.

Interested in new technology? Check out the Fool's new report, "The Next Trillion Dollar Revolution." Claim your free copy by clicking here.

Read the original:
A Growth-Free Quarter -- and That's OK

Posted in Genetics | Comments Off on A Growth-Free Quarter — and That's OK

Stem cells thrive on superficial relationships

Posted: August 11, 2012 at 12:14 am

Figure 1: iPSCs cultivated atop a 'feeder' layer of mouse embryonic fibroblasts (top left) maintain expression of a fluorescent pluripotency marker (top right; green). However, these cells also thrive (bottom left) and maintain their pluripotency (bottom right) when grown on a glutaraldehyde-fixed feeder cell layer. Image reproduced under the terms of the CCAL, with copyright shared by Yue et al

Stem cells are renowned for their capacity to develop into a wide range of mature cell types but they cannot maintain this flexibility on their own. In the body, neighboring cells help maintain this pluripotent state. But to grow these cells in culture, scientists have had to devise a variety of specialized techniques.

This is especially true for embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), which are ESC-like cells derived from adult tissue. To preserve their pluripotency, these cells have typically been grown atop a supporting layer of feeder cells. Now, a strategy developed by a team led by Yoshihiro Ito at the RIKEN Advanced Science Institute, Wako, promises to make ESC and iPSC cultivation considerably easier.

Feeder cells provide valuable growth factors for stem cells but also make culture complicated and create opportunities for contaminationan especially serious concern for clinical applications. Early attempts to isolate the key features of feeder cells have fallen short. It was difficult to culture stem cells on growth-factor immobilized substrates, says Ito. Feeder cells provide a complex microenvironment that cannot simply be replaced with one or several growth factors.

As an alternative, the researchers subjected feeder cell layers to chemical fixation treatments that killed the cells while physically preserving them and maintaining their external structure largely intact. This resulted in a robust cell culture surface that retained virtually all of the features with which stem cells would typically interact. Mouse iPSCs maintained their pluripotent state even after extensive cultivation on feeder cells that had previously been fixed with either formaldehyde (FA) or glutaraldehyde (GA). GA fixation is a harsher treatment, but Ito and colleagues noted that GA fixed cells also provided a superior substrate, and this GA-fixed layer was robust enough to be washed and reused.

The researchers were pleasantly surprised to find that mouse iPSCs grown in this manner were virtually indistinguishable from those cultured by traditional methods (Fig. 1). Feeder cells were believed to secrete proteins or other compounds that maintain the growth of undifferentiated stem cells, says Ito. But fixed cells lose this secretion capability, which shows that providing the right contact microenvironment is more important for iPSCs. Given how rugged the fixed cell layers are, he anticipates that this approach could offer a commercially viable cell culture tool once it has been tested and optimized for cultivation of human iPSCs.

More information: Yue, X.-S., Fujishiro, M., Nishioka, C., Arai, T., Takahashi, E., Gong, J.-S., Akaike, T. & Ito, Y. Feeder cells support the culture of induced pluripotent stem cells even after chemical fixation. PLoS ONE 7, e32707 (2012). http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0032707

Provided by RIKEN

Follow this link:
Stem cells thrive on superficial relationships

Posted in Stem Cell Videos | Comments Off on Stem cells thrive on superficial relationships

Stem cells may prevent post-injury arthritis

Posted: August 10, 2012 at 11:15 pm

Public release date: 10-Aug-2012 [ | E-mail | Share ]

Contact: Mary Jane Gore mary.gore@duke.edu 919-660-1309 Duke University Medical Center

DURHAM, N.C.-- Duke researchers may have found a promising stem cell therapy for preventing osteoarthritis after a joint injury.

Injuring a joint greatly raises the odds of getting a form of osteoarthritis called post-traumatic arthritis, or PTA. There are no therapies yet that modify or slow the progression of arthritis after injury.

Researchers at Duke University Health System have found a very promising therapeutic approach to PTA using a type of stem cell, called mesenchymal stem cells (MSCs), in mice with fractures that typically would lead to them developing arthritis. Their findings could lead to a therapy that would be used after joint injury and before signs of significant osteoarthritis.

The scientists thought the stem cells would work to prevent PTA by altering the balance of inflammation and regeneration in knee joints, because these stem cells have beneficial properties in other regions of the body.

"The stem cells were able to prevent post-traumatic arthritis," said Farshid Guilak, Ph.D., director of orthopaedic research at Duke and senior author of the study.

The study was published on August 10 in Cell Transplantation.

The researchers also thought that a type of mice bred for their super-healing properties would probably fare better than typical mice, but they were wrong.

"We decided to investigate two therapies for the study, said lead author Brian Diekman, Ph.D., a postdoctoral researcher in the Guilak lab. "We thought that stem cells from so-called superhealer mice would be superior at providing protection, and instead, we found that they were no better than stem cells from typical mice. We thought that maybe it would take stem cells from superhealers to gain an effect as strong as preventing arthritis after a fracture, but we were surprised and excited to learn that regular stem cells work just as well."

More here:
Stem cells may prevent post-injury arthritis

Posted in Cell Therapy | Comments Off on Stem cells may prevent post-injury arthritis

Stem cells thrive on superficial relationships

Posted: August 10, 2012 at 9:13 pm

Figure 1: iPSCs cultivated atop a 'feeder' layer of mouse embryonic fibroblasts (top left) maintain expression of a fluorescent pluripotency marker (top right; green). However, these cells also thrive (bottom left) and maintain their pluripotency (bottom right) when grown on a glutaraldehyde-fixed feeder cell layer. Image reproduced under the terms of the CCAL, with copyright shared by Yue et al

Stem cells are renowned for their capacity to develop into a wide range of mature cell types but they cannot maintain this flexibility on their own. In the body, neighboring cells help maintain this pluripotent state. But to grow these cells in culture, scientists have had to devise a variety of specialized techniques.

This is especially true for embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), which are ESC-like cells derived from adult tissue. To preserve their pluripotency, these cells have typically been grown atop a supporting layer of feeder cells. Now, a strategy developed by a team led by Yoshihiro Ito at the RIKEN Advanced Science Institute, Wako, promises to make ESC and iPSC cultivation considerably easier.

Feeder cells provide valuable growth factors for stem cells but also make culture complicated and create opportunities for contaminationan especially serious concern for clinical applications. Early attempts to isolate the key features of feeder cells have fallen short. It was difficult to culture stem cells on growth-factor immobilized substrates, says Ito. Feeder cells provide a complex microenvironment that cannot simply be replaced with one or several growth factors.

As an alternative, the researchers subjected feeder cell layers to chemical fixation treatments that killed the cells while physically preserving them and maintaining their external structure largely intact. This resulted in a robust cell culture surface that retained virtually all of the features with which stem cells would typically interact. Mouse iPSCs maintained their pluripotent state even after extensive cultivation on feeder cells that had previously been fixed with either formaldehyde (FA) or glutaraldehyde (GA). GA fixation is a harsher treatment, but Ito and colleagues noted that GA fixed cells also provided a superior substrate, and this GA-fixed layer was robust enough to be washed and reused.

The researchers were pleasantly surprised to find that mouse iPSCs grown in this manner were virtually indistinguishable from those cultured by traditional methods (Fig. 1). Feeder cells were believed to secrete proteins or other compounds that maintain the growth of undifferentiated stem cells, says Ito. But fixed cells lose this secretion capability, which shows that providing the right contact microenvironment is more important for iPSCs. Given how rugged the fixed cell layers are, he anticipates that this approach could offer a commercially viable cell culture tool once it has been tested and optimized for cultivation of human iPSCs.

More information: Yue, X.-S., Fujishiro, M., Nishioka, C., Arai, T., Takahashi, E., Gong, J.-S., Akaike, T. & Ito, Y. Feeder cells support the culture of induced pluripotent stem cells even after chemical fixation. PLoS ONE 7, e32707 (2012). http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0032707

Provided by RIKEN

Go here to see the original:
Stem cells thrive on superficial relationships

Posted in Stem Cells | Comments Off on Stem cells thrive on superficial relationships

Stem cells may prevent post-injury arthritis

Posted: August 10, 2012 at 9:12 pm

Public release date: 10-Aug-2012 [ | E-mail | Share ]

Contact: Mary Jane Gore mary.gore@duke.edu 919-660-1309 Duke University Medical Center

DURHAM, N.C.-- Duke researchers may have found a promising stem cell therapy for preventing osteoarthritis after a joint injury.

Injuring a joint greatly raises the odds of getting a form of osteoarthritis called post-traumatic arthritis, or PTA. There are no therapies yet that modify or slow the progression of arthritis after injury.

Researchers at Duke University Health System have found a very promising therapeutic approach to PTA using a type of stem cell, called mesenchymal stem cells (MSCs), in mice with fractures that typically would lead to them developing arthritis. Their findings could lead to a therapy that would be used after joint injury and before signs of significant osteoarthritis.

The scientists thought the stem cells would work to prevent PTA by altering the balance of inflammation and regeneration in knee joints, because these stem cells have beneficial properties in other regions of the body.

"The stem cells were able to prevent post-traumatic arthritis," said Farshid Guilak, Ph.D., director of orthopaedic research at Duke and senior author of the study.

The study was published on August 10 in Cell Transplantation.

The researchers also thought that a type of mice bred for their super-healing properties would probably fare better than typical mice, but they were wrong.

"We decided to investigate two therapies for the study, said lead author Brian Diekman, Ph.D., a postdoctoral researcher in the Guilak lab. "We thought that stem cells from so-called superhealer mice would be superior at providing protection, and instead, we found that they were no better than stem cells from typical mice. We thought that maybe it would take stem cells from superhealers to gain an effect as strong as preventing arthritis after a fracture, but we were surprised and excited to learn that regular stem cells work just as well."

Here is the original post:
Stem cells may prevent post-injury arthritis

Posted in Cell Therapy | Comments Off on Stem cells may prevent post-injury arthritis

Scientists find the stem cells that drive our creativity

Posted: August 10, 2012 at 8:12 am

Researcher find master cells also key for abstract thought and planning ahead Breakthrough could lead to new treatments for autism

By Mark Prigg

PUBLISHED: 13:00 EST, 9 August 2012 | UPDATED: 13:00 EST, 9 August 2012

A newly-discovered type of stem cell could be the key to higher thinking in humans, research suggests.

Scientists have identified a family of stem cells that may give birth to neurons responsible for abstract thought and creativity.

The cells were found in embryonic mice, where they formed the upper layers of the brains cerebral cortex.

Researchers hope the breakthrough could lead to new treatments for disorders such as autism

In humans, the same brain region allows abstract thinking, planning for the future and solving problems.

Previously it was thought that all cortical neurons - upper and lower layers - arose from the same stem cells, called radial glial cells (RGCs).

The new research shows that the upper layer neurons develop from a distinct population of diverse stem cells.

See the original post:
Scientists find the stem cells that drive our creativity

Posted in Stem Cell Videos | Comments Off on Scientists find the stem cells that drive our creativity

Page 2,674«..1020..2,6732,6742,6752,676..2,6802,690..»